The United States has a drug problem. That is not a controversial statement. What is more complicated is what American drug policy has chosen to do about it, and what it has chosen to stop doing.

In December 2025, President Trump signed an executive order instructing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act. On the same watch, the administration began gutting the federal agencies responsible for preventing overdose deaths, attempted to pull back $11 billion in public health funding from states and local departments, and pushed a budget proposal that would cut more than $1 billion from the Substance Abuse and Mental Health Services Administration. The agency whose entire purpose is to keep Americans alive through addiction and mental health crises.

This is the United States of America drug policy story of 2025. One hand loosening restrictions on a drug with significant harm potential. The other pulling funding from the infrastructure that catches people when drugs destroy their lives.

Rescheduling Marijuana: What It Actually Means

The move to reschedule marijuana has been years in the making. The Biden administration initiated the federal review process in 2022. The Department of Health and Human Services recommended rescheduling to Schedule III in 2023. The Department of Justice issued a proposed rule in 2024. Trump’s December 2025 executive order instructed the process be completed.

Schedule III status does not legalise marijuana at the federal level. What it does is formally acknowledge that marijuana has accepted medical uses and a lower abuse potential than Schedule I substances like heroin. For the research community, this matters: DEA restrictions that have historically made cannabis clinical research extraordinarily difficult would be reduced. The medical marijuana industry would see significant implications around taxation and insurance coverage. Public health advocates watching from the sidelines, however, are left with a more uncomfortable question.

Rescheduling sends a signal. It normalises. It tells communities, parents, and young people that the federal government has reassessed its position on cannabis. That is not a neutral act. The evidence on cannabis harm, particularly for adolescent brain development, for people with mental health vulnerabilities, and for those who develop cannabis use disorder, has not shifted to justify that signal. What has shifted is the political and commercial calculus.

The CDC data on US overdose deaths shows a 26.2 per cent decline in drug overdose fatalities between 2023 and 2024, the largest single-year drop in a decade. That is genuinely significant. Approximately 79,384 people died from drug overdoses in 2024, compared to 105,007 the year before. The reduction is attributed to expanded naloxone access, the removal of the buprenorphine prescribing waiver, and shifts in the illicit drug supply.

But the headline figure obscures what is happening underneath it. Deaths continued rising in some Western states and specific counties. Geographic disparities are stark. And the communities seeing continued increases are often those with the fewest prevention resources to begin with.

The Administration Cutting the Safety Net

The overdose decline did not happen by accident. It happened because of sustained investment in treatment access, harm reduction infrastructure, and the workforce trained to deliver both. That investment is now being systematically dismantled.

Significant workforce reductions at SAMHSA began in February 2025. The Trump administration’s budget proposals call for more than $1 billion in cuts to the agency. The KFF tracker documents the scale of what has been walked back: cancelled school-based mental health grants, rescinded community violence intervention funding, proposals to restructure or eliminate SAMHSA entirely under a new agency called the Administration for a Healthy America.

The NIH faces proposed cuts of $18 billion under the same restructuring plan. NIDA, the National Institute on Drug Abuse, currently funds roughly 85 per cent of global addiction research. Putting that in limbo does not just affect American research. It affects the global evidence base for what works in addiction treatment.

States are already feeling the impact. Texas shut down a 24-hour call line supporting people in addiction and mental health crisis after federal funding was withdrawn. These are not abstract policy shifts. They are people losing access to support at the moment they most need it.

The bipartisan SUPPORT for Patients and Communities Reauthorization Act was signed into law, extending funding for overdose prevention and behavioural health services through 2030. That is a genuine positive. But one piece of legislation does not offset the systematic withdrawal of the federal infrastructure built over the past decade to address the opioid crisis.

Fentanyl as Foreign Policy

What makes the American position particularly contradictory is the role drug policy has taken in geopolitics. In early 2025, the Trump administration imposed tariffs on Mexico, China, and Canada specifically as punishment for trafficking fentanyl and its precursor chemicals into the United States.

The use of trade policy as a drug enforcement tool is not without precedent, but the scale and framing here is notable. Fentanyl has been positioned as a national security threat, a foreign invasion, an act of economic warfare. The political language is designed to externalise the crisis, to locate its cause across borders rather than in domestic conditions of despair, disconnection, and inadequate prevention infrastructure.

That framing is convenient. It is also wrong.

Fentanyl kills Americans because there is demand for it. That demand exists because prevention investment has been insufficient, because treatment access remains patchy, because communities experiencing economic devastation have not been supported with the resilience-building resources that reduce uptake in the first place. Imposing tariffs on Mexico does not address any of those conditions. It does not build a single prevention programme, train a single community worker, or reach a single young person before drug use begins.

The CDC data shows synthetic opioids other than methadone, primarily fentanyl, were involved in 55,076 deaths in 2024, down from 74,189 in 2023. A significant reduction. But 55,076 is still 55,076 families. Still 55,076 preventable deaths. Treating that number as evidence that the approach is working misses the scale of what remains.

What a Prevention-First Response Would Look Like

The US overdose crisis did not begin with fentanyl. It began decades earlier, with overprescribing, with communities left without economic purpose, with young people who had no strong protective factors against drug use when it became available. Fentanyl made it catastrophically more lethal. It did not create the conditions for it.

A prevention-first response to the US drug crisis would look different from what is currently happening. Early education and family resilience would receive investment rather than seeing school-based mental health grants cut. Building the treatment workforce would take priority over reducing SAMHSA. Above all, the opioid crisis would be treated as a domestic failure requiring domestic solutions rather than a foreign attack requiring trade sanctions.

The 26 per cent drop in overdose deaths in 2024 is real and it matters. It shows that when resources go into evidence-based intervention, people live. The question the United States needs to answer is whether it is prepared to sustain and expand that investment, or whether it will dismantle the infrastructure that produced those gains while pursuing a policy agenda that signals cannabis is acceptable, treatment funding is excessive, and fentanyl is someone else’s problem.

Families who have lost someone to overdose know the answer to that question. They knew it before the data did.